Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy

Oncology

Volumn 65, Issue 1, 2003, Pages 14-22

  Graf, R ^a   Wust, Peter ^a,d   Hildebrandt, B ^a   Gogler H ^b   Ullrich, R ^a   Herrmann, R ^c   Riess, H ^a   Felix, R ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b DRK Klinik   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anal cancer; Overall treatment time; Radiation dose; Radiochemotherapy; Treatment interruption

Indexed keywords

FLUOROURACIL; MITOMYCIN;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GAMMA RADIATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RADIATION DOSAGE; SURVIVAL ANALYSIS; SWITZERLAND; TREATMENT OUTCOME;

EID: 0038648324     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071200     Document Type: Article

References (28)

1. Nigro ND, Vaitkevicius VK, Considine B: Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 1974;17:354-356.
2. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-2049.
3. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539.
4. UKCCCR Anal Cancer Trial Working Party. UK Co-Ordinating Committee on Cancer Research: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049-1054.
5. Shank B, Cunningham JD, Kelsen DP: Cancer of the anal region; in De Vita V, Hellmann S, Rosenberg SA: Cancer - Principles and Practice of Oncology, ed 5. Philadelphia-New York, Lippincott Raven, 1997, pp 1234-1251.
6. Ryan DP, Compton CC, Mayer RJ: Carcinoma of the anal canal. N Engl J Med 2000;342:792-800.
7. Cummings BJ: Anal canal carcinomas. Front Radiat Ther Oncol 1992;26:131-141.
8. Cummings BJ: Anal canal cancer - To split or not to split? Cancer J Sci Am 1996;2:194-196.
9. Fowler JF, Lindstrom MJ: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-467.
10. Cummings BJ: Benefits of accelerated hyper-fractionation for head and neck cancer. Acta Oncol 1999;38:131-136.
11. Wong CS, Tsang RW, Cummings BJ, Fyles AW, Couture J, Brierley JD, Pintilie M: Proliferation parameters in epidermoid carcinomas of the anal canal. Radiother Oncol 2000;56:349-353.
12. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Catton CN: Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21:1115-1125.
13. Spiessl B, Beahrs OH, Hermanek P: TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. Berlin, Springer, 1992.
14. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-694.
15. Kaplan EL, Meier P: Nonparamatric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
17. John M, Pajak T, Flam M, et al: Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2:205-211.
18. John MJ, Pajak T, Kreig R, Pinover WH, Myerson R: Dose escalation without split-course chemoradiation for anal cancer: Results of a phase II RTOG Study (abstract 136). Int J Radiat Oncol Biol Phys 1997;39(S2):203.
19. Robertson C, Robertson AG, Hendry JH, et al: Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 1998;40:319-329.
20. Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF: Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997;39:651-657.
21. Weber DC, Kurtz JM, Allal AS: The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001;50:675-680.
22. Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM: The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 1997;79:2329-2335.
23. Ceresoli GL, Ferreri AJ, Cordio S, Vill E: Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases. Oncology 1998;55:525-532.
24. Ngan S, Smith J, Chao M, Lim-Joon D, Guiney M: Impact of treatment interruption on outcome of chemoradiation for carcinoma of anus (abstract 2113). Int J Radiat Oncol Biol Phys 1998;42(S1):284.
25. Schneider I, Grabenbauer GG, Reck T, Kockerling F, Sauer R, Gall FP: Combined radiation and chemotherapy for epidermoid carcinoma of the anal canal. Int J Colorectal Dis 1992;7:192-196.
26. Robertson G, Parmar M, Foy C, Griffiths G, Saunders M, Dische S: Overall treatment time and the conventional arm of the CHART trial in the radiotherapy of head and neck cancer. Radiother Oncol 1999;50:25-28.
27. Smith DE, Shah KH, Rao AR, Frost DB, Latino F, Anderson PJ, Peddada AV, Kagan AR: Cancer of the anal canal: Treatment with chemotherapy and low-dose radiation therapy. Radiology 1994;191:569-572.
28. Taylor JM, Withers HR: Influence of selection bias on dose-time analysis: A theoretical investigation. Radiother Oncol 1996;40:259-270.